Date Time
Dana-Farber Cancer Institute faculty recognized as 2021 ASCO leaders in cancer care
The American Society of Clinical Oncology (ASCO) recognized two Dana-Farber Cancer Institute researchers as winners of ASCO’s Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.
Among the recipients:
Jennifer A. Ligibel, MD is the Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living and the Director of the Center for Faculty Well-Being at Dana-Farber Cancer Institute, as well as an Associate Professor of Medicine at Harvard Medical School. Dr. Ligibel has dedicated her career to studying the role of exercise and weight management in the prevention and treatment of breast cancer and is a senior physician at the Susan F. Smith Center for Women’s Cancer at Dana-Farber. The Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award honors Dr. Ligibel as an extraordinary f
Johns Hopkins Health Policy Forum hosts conversation with CDC Director Rochelle Walensky
jhu.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jhu.edu Daily Mail and Mail on Sunday newspapers.
Are linen face masks effective? We asked an expert
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Transgender Hormone Therapy Tied to Blood Pressure Risk by Colleen Fleiss on April 20, 2021 at 3:31 PM Blood pressure levels were higher in transgender males, and lower in transgender females The study underscores the importance of monitoring blood pressure and preventive screening measures in transgender patients
In transgender men and women, the gender-affirming hormone therapy (GAHT) is linked to blood pressure changes, said physician-researchers from Beth Israel Deaconess Medical Center (BIDMC). The study appears in Hypertension, a journal of the American Heart Association. There are many important gaps in clinicians knowledge about the effects of hormone therapy for transgender people, said senior author Michael S. Irwig, MD, Director of Transgender Medicine at BIDMC. Our study sought to address these gaps by recruiting a racially and ethnically diverse pool of participants to examine the time course and magnitude of the effects of gender-aff
Gender-affirming hormone therapy linked to blood pressure changes in transgender people
Gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women, according to new research published today in
Hypertension, an American Heart Association journal.
Given the higher burden of heart attack, stroke and other cardiovascular conditions among transgender men and women, blood pressure screening and monitoring are important, especially after beginning hormone therapies.
Although doctors have prescribed gender-affirming hormone therapy to transgender men and women for more than 25 years, researchers and health care professionals know little about rates of hypertension and how the effects on blood pressure change over time. Previous research has shown that transgender men were almost five times as likely to report having a heart attack compared to cisgender women.